Home › Funds › Sarissa Capital Management LP › NBIX
Sarissa Capital Management LP position in NBIX
NEUROCRINE BIOSCIENCES INC · Health Care
Sarissa Capital Management LP reported holding 116,533 shares of NBIX (NEUROCRINE BIOSCIENCES INC) in its Q2 2026 13F filing — a position valued at US$19.6M, representing 11.04% of its reported portfolio and ranking #4 among its reported holdings. Sarissa Capital Management LP has disclosed NBIX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Sarissa Capital Management LP's NBIX position evolved
Sarissa Capital Management LP first disclosed a stake in NBIX in Q3 2023 at 366,000 shares (US$41.2M). The position peaked in Q4 2023 at 470,000 shares, worth US$61.9M. Across 12 filings, Sarissa Capital Management LP increased the stake 2 time(s), trimmed it 4 time(s) and left it unchanged 5 time(s). The most recent filing (Q2 2026) shows 116,533 shares valued at US$19.6M. Notable position changes include a 28% increase in Q4 2023 (shares rose 5% over the following quarter), a 26% trim in Q1 2024 (shares were roughly flat over the following quarter), a 62% trim in Q1 2026 (shares rose 28% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 366.00K | $41.17M | New |
| Q4 2023 | 470.00K | $61.93M | Add |
| Q1 2024 | 346.43K | $47.78M | Reduce |
| Q2 2024 | 410.48K | $56.51M | Add |
| Q3 2024 | 410.48K | $47.30M | Hold |
| Q4 2024 | 309.12K | $42.19M | Reduce |
| Q1 2025 | 309.12K | $34.19M | Hold |
| Q2 2025 | 303.15K | $38.10M | Reduce |
| Q3 2025 | 303.15K | $42.56M | Hold |
| Q4 2025 | 303.15K | $43.00M | Hold |
| Q1 2026 | 116.53K | $15.35M | Reduce |
| Q2 2026 | 116.53K | $19.64M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About NBIX and 13F data
NBIX (NEUROCRINE BIOSCIENCES INC) is a Health Care company. 34 other funds we track also report a position in NBIX — the largest reported positions include Renaissance Technologies (US$393.7M), Two Sigma Investments (US$349.9M), Vestal Point Capital, LP (US$316.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding NBIX
- Renaissance Technologies 2.34M sh · $393.68M · Q2 2026
- Two Sigma Investments 2.08M sh · $349.92M · Q2 2026
- Vestal Point Capital, LP 1.88M sh · $316.85M · Q2 2026
- RTW INVESTMENTS, LP 1.27M sh · $213.69M · Q2 2026
- IEQ CAPITAL, LLC 640.30K sh · $107.91M · Q2 2026
More on Sarissa Capital Management LP
FAQ
How long has Sarissa Capital Management LP held NBIX?
Sarissa Capital Management LP has disclosed NBIX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Sarissa Capital Management LP's current position in NBIX?
As of Q2 2026, Sarissa Capital Management LP holds 116.53K shares of NBIX (NEUROCRINE BIOSCIENCES INC), valued at $19.64M, representing 11.04% of its reported portfolio and ranking #4.
Has Sarissa Capital Management LP been buying or selling NBIX?
In the latest 13F filing (Q2 2026), Sarissa Capital Management LP held unchanged its position in NBIX. The position peaked in Q4 2023 at 470.00K shares.
Which other funds hold NBIX?
Other major institutional holders of NBIX include Renaissance Technologies, Two Sigma Investments, Vestal Point Capital, LP, among 34 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.